In Health-Care


• Through the Capitall Cell platform
• Project approved by the BioEXpert Netwrok
• Social Impact (Ship2B)



Multi-billion dollar opportunity in the $85B autoinjectors market: Anaphylaxis (ADRENALINE / EPINEPHRINE), Adrenal crisis (HYDROCORTISONE) , Asthma (TERBUTALINE) , Diabetes (INSULIN) , Epileptic seizure (MIDAZOLAM) , Growth Hormone (OMNITROPE), Hypercholesterolemia (EVOCUMAB), Hypoglycemia (GLUCAGON), Migraines and cluster headaches (SUMATRIPAN), Opioid Overdose (NALOXONE) , Osteoporosis (TERIPARATIDA), Rheumatoid arthritis (METHOTREXATE), Sclerosis (INTERFERON BETA 1B), Temporary paralysis in Parkinson’s disease (APOMORPHINE)… more than 300M users by 2026.

Key players:

Ready To Market

  • Solid regulatory strategy (CE Mark, ongoing FDA clearance)
  • US patent US2018/0061208A1 (in process: EU, Japan, China)
  • Clinical Evidence from first Clinical Trial NCT02854969
  • Pharma partnership conversations (Under NDA)
  • Support letters from Medical KOLs and patients associations
  • Extended pipeline, with wide Big-data opportunities
  • High seasoned and proved team lead by Dr. Joaquim Trias (2 IPO, 4 M&A)

We keep an active approach to provide transparency into our business, development programs and scientific results in a clear and timely manner, as the best way to maintain the confidence of our shareholders, through company announcements, investor meetings, and company presentations so we encourage shareholders, potential investors, investment analysts and other external stakeholders to contact us.

Request More Information

Source: Silicon Valley Bank